Glenmark Lifesciences Q3 Results Date, GLS was owned by Glenmark Pharma. GLS run its business with 137 APIs in its portfolio. Powered by our massive, world-class manufacturing and research capabilities, we supply high-quality APIs to more than 700 pharma companies in multiple countries.
Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
The company has two key segments – Generics and Complex APIs (90% of the revenue) and Contract Development and Manufacturing Operations (CDMO) (8% of the revenue).
GLS is a leading manufacturer of selected specialized APIs for chronic therapeutic areas like Cardio Vascular disease, diabetes, and pain management, and others. The company has leadership in select high value non-commercialized APIs in chronic therapeutic areas.
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, January 27, 2023, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third quarter and Nine months ended December 31, 2022.
Target Price of Glenmark Lifesciences ?
BofA Securities maintained a buy rating on Glenmark Life with a target price of Rs 560. Sustainable growth drivers are in focus.
Diversifying customer base through new addition and going forward portfolio expansion is the key to offset price pressure, it said.
“CDMO is the next growth lever. Along with that capacity, expansion is likely to aid growth,” said the note.
BOB Capital Markets has been bullish on Glenmark Life Sciences Ltd and suggests buying for a target price of Rs 620/share.
Glenmark Life Sciences is a pioneer in the development and manufacture of high-value, non-commoditized Active Pharmaceutical Ingredients (APIs) for chronic diseases.